<DOC>
	<DOCNO>NCT00299520</DOCNO>
	<brief_summary>This multi-center , investigator-blind , comparative Phase 3 study . Patients receive either iclaprim linezolid 10 14 day . Patients evaluate daily first four day study treatment every day , 14 day treatment period , End Therapy , Test Of Cure visit ( 7 14 day post treatment ) , Late Follow-up ( F/U ) visit ( 7 14 day TOC visit ) .</brief_summary>
	<brief_title>Phase 3 Safety Efficacy Study I.V . Iclaprim v Linezolid cSSSI ( ASSIST-1 )</brief_title>
	<detailed_description>Primary Objective : The primary objective study compare clinical cure rate iclaprim linezolid test cure ( TOC ) visit ( 7 14 day end treatment ) . Secondary Objectives : The secondary objective study compare iclaprim linezolid regarding : - Clinical efficacy end study medication treatment ; - Time resolution systemic local sign symptom complicate skin skin structure infection ( cSSSI ) ; - Clinical outcome microbiologically evaluable ( ME ) population ; - Bacteriologic outcome ME population ; - Bacteriologic eradication rate Baseline ( BL ) pathogens ; - Clinical outcome modify intent-to-treat ( MITT ) population ; - Bacteriologic outcome MITT population ; - Baseline vitro susceptibility isolate pathogen ME population ; - Safety tolerability iclaprim treatment .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<mesh_term>Iclaprim</mesh_term>
	<criteria>Inclusion Criteria Diagnosis infection consistent complicate skin skin structure infection due gram positive pathogen . Known suspected hypersensitivity study medication relate antiinfective medication Any know suspected condition concurrent treatment contraindicate prescribe information Previous enrollment study Treatment investigational drug within 30 day enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>skin infection</keyword>
	<keyword>complicate skin infection</keyword>
	<keyword>skin structure infection</keyword>
</DOC>